Fusion gene for modifying mesenchymal stem cells, plasmid, stem cells obtained through modification and preparation method

Abstract

The invention discloses a fusion gene for modifying mesenchymal stem cells, a plasmid, stem cells obtained through modification and a preparation method. The fusion gene comprises a Klotho nucleic acid artificial sequence, a self-shearing polypeptide T2A nucleic acid artificial sequence and an FGF23 nucleic acid artificial sequence, and the Klotho nucleic acid artificial sequence, the self-shearing polypeptide T2A nucleic acid artificial sequence and the FGF23 nucleic acid artificial sequence are sequentially connected in series. The mesenchymal stem cells modified by the fusion gene prepared by the invention are obviously higher than normal stem cells Klotho and FGF23 in expression quantity, and the continuous expression effect on the Klotho and the FGF23 can be realized.

Description

technical field

[0001] The invention relates to the technical field of genetic engineering, in particular to a fusion gene and a plasmid for modifying mesenchymal stem cells, stem cells obtained through modification and a preparation method. Background technique

[0002] Chronic kidney disease (CKD) is a growing international problem, affecting 753 million people worldwide in 2016, including 417 million women and 336 million men. Kidney Klotho RNA is reduced in CKD patients, a clinical observation confirmed in many preclinical models. Moreover, unilateral nephrectomy and contralateral ischemia-reperfusion injury can down-regulate the expression of renal Klotho protein and mRNA. Klotho expression was also reduced in the chronic glomerulonephritis model. Klotho overexpression improves renal function and improves renal histology. Coronary artery calcification is very prevalent in CKD patients, increasing cardiovascular morbidity and mortality. Klotho-FGF23 plays an importan...

Images